Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cediranib maleate
Drug: gemcitabine hydrochloride

First Posted Date: 2006-05-17

Last Posted Date: 2017-03-21

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 101

Registration Number: NCT00326599

Locations: 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸
McDonough District Hospital, Macomb, Illinois, United States
🇺🇸
Holland Community Hospital, Holland, Michigan, United States

and more 148 locations

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: liposomal doxorubicin
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2006-05-16

Last Posted Date: 2023-03-27

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 820

Registration Number: NCT00326456

Locations: 🇵🇹
CHC Maternidade Bissaya-Barreto, Gynecology Unit, Coimbra, Portugal
🇮🇹
Ospedale di Bentivoglio, Bentivoglio, BO, Italy
🇮🇹
Azienda Ospedaliera S. Giuseppe Moscati, U.O. di Oncologia Medica, Monteforte Irpino, AV, Italy

and more 35 locations

Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Pemetrexed
Drug: Gemcitabine
Drug: Carboplatin
Drug: Vinorelbine

First Posted Date: 2006-05-12

Last Posted Date: 2011-05-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 135

Registration Number: NCT00325234

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Phase 2

Conditions: Lymphoma, Non-Hodgkin
Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Ondansetron
Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Acetaminophen
Other: PET Scan
Drug: Ifosfamide
Drug: Mesna (IV)
Drug: Mesna (oral)
Drug: Carboplatin
Drug: Etoposide
Drug: Rituximab

First Posted Date: 2006-05-11

Last Posted Date: 2021-07-22

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 150

Registration Number: NCT00324467

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Bevacizumab
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2006-05-10

Last Posted Date: 2016-09-07

Lead Sponsor: Stanford University

Target Recruit Count: 48

Registration Number: NCT00323869

Locations: 🇺🇸
Santa Clara Valley Medical Center, San Jose, California, United States
🇺🇸
VA Palo Alto Healthcare System, Palo Alto, California, United States
🇺🇸
Stanford University School of Medicine, Stanford, California, United States

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-05-08

Last Posted Date: 2013-11-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 1329

Registration Number: NCT00322452

Locations: 🇹🇭
Research Site, Songkla, Thailand

Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

Phase 2

Terminated

Conditions: Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Ovarian Cancer
Mixed Tumor, Mesodermal

Interventions: Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-05-08

Last Posted Date: 2018-09-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00322881

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

Phase 2

Completed

Conditions: brca1 Mutation Carrier
brca2 Mutation Carrier
Breast Cancer
Hereditary Breast/Ovarian Cancer (brca1, brca2)

First Posted Date: 2006-05-04

Last Posted Date: 2013-08-26

Lead Sponsor: University College London Hospitals

Target Recruit Count: 148

Registration Number: NCT00321633

Locations: 🇮🇱
Naharia Hospital, Naharia, Israel
🇬🇧
Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom
🇬🇧
UCL Cancer Institute, Hampstead, London, England, United Kingdom

and more 22 locations

A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-04-26

Last Posted Date: 2010-05-11

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 47

Registration Number: NCT00318136

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Not Applicable

Conditions: Lymphoma

First Posted Date: 2006-04-24

Last Posted Date: 2015-09-25

Lead Sponsor: European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma

Target Recruit Count: 96

Registration Number: NCT00317408

Locations: 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪
Krankenhaus Muenchen Schwabing, Munich, Germany

and more 91 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy